Erevidge – pro
Basal cell carcinoma (BCC) (also known as basalioma or basal cell cancer), is the most common skin cancer, and one of the most common cancers in the United States. Approved in 2012, vismodegib is used to treat an advanced form of basal-cell carcinoma. In a multicenter, international, two-cohort, nonrandomized study, patients with metastatic basal-cell carcinoma and those with locally advanced basal-cell carcinoma who had inoperable disease or for whom surgery was inappropriate (because of multiple recurrences and a low likelihood of surgical cure, or substantial anticipated disfigurement) received Erevidge. All patients received 150 mg of oral Erevidge (vismodegib) daily. In 33 patients with metastatic basal-cell carcinoma, the independently assessed response rate was 30%. In 63 patients with locally advanced basal-cell carcinoma, the independently assessed response rate was 43%. On this basis the drug was approed. However, there is no evidence supporting continuing this drug past the point of progression.
Aleksandar Sekulic, M.D., Ph.D., Michael R. Migden, M.D., Anthony E. Oro, M.D., Ph.D., Luc Dirix, M.D., Ph.D., Karl D. Lewis, M.D., John D. Hainsworth, M.D., James A. Solomon, M.D., Ph.D., Simon Yoo, M.D., Sarah T. Arron, M.D., Ph.D., Philip A. Friedlander, M.D., Ph.D., Ellen Marmur, M.D., Charles M. Rudin, M.D., Ph.D., Anne Lynn S. Chang, M.D., Jennifer A. Low, M.D., Ph.D., Howard M. Mackey, Ph.D., Robert L. Yauch, Ph.D., Richard A. Graham, Ph.D., Josina C. Reddy, M.D., Ph.D., and Axel Hauschild, M.D.Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma. N Engl J Med 2012; 366:2171-2179
Erevidge, prescribing Information 2017